Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency In Dec, 2019 Kamada signed a deal with Alvotech for commercialization of biosimilars in Israel while Techno Science also signed an agreement with Kishi Kasei for co-developing biosimilar aflibercept Mylan and Biocon launched its Ogivri (trastuzumab-dkst) in…